ASKA Pharmaceutical Holdings (4886) · InitiativeRestated
Expanding the Business in Disease Prevention and Pre-Disease Care
First written in FY2022-Q1. 1 of 2 entries say "Restated". Latest entry: FY2022.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Business Expansion into Disease Prevention and the Pre-Disease DomainA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2022RestatedAnnual report
「国は疾病予防や未病領域への投資を強めており、したがってこの領域での事業を積み増すことが弊社の経営の安定に寄与するものと考えております。」
疾病予防・未病領域への事業積み増しを、経営安定に寄与する方針として再掲している。 - FY2022-Q1First statedAnnual report
「The government is increasing investment in disease prevention and pre-disease care. We therefore believe that expanding our business in these areas will contribute to management stability.」
The company indicates a policy of expanding its business in disease prevention and pre-disease care against the backdrop of increased government investment in these areas.